Featured Research

from universities, journals, and other organizations

Combined therapy benefits cigarette smokers trying to quit compared to monotherapy

Date:
January 7, 2014
Source:
Mayo Clinic
Summary:
Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year.

Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month in JAMA.

"We were interested in seeing if combining different medications together can improve the ability of patients to quit over and above single drug therapy," says lead author Jon Ebbert, M.D., Mayo Clinic Nicotine Dependence Center. "What we found was an increase in quit rates, and the increase in quit rates was particularly strong in heavier and more dependent smokers."

The study authors looked at the efficacy of combining the medications varenicline and bupropion SR (sustained-release) for smoking cessation, compared with varenicline alone (monotherapy). In addition, the research team analyzed data based on participants' smoking rate and level of nicotine dependence.

Cigarette smokers were randomized to 12 weeks of varenicline and bupropion SR or varenicline and placebo with follow-up through 52 weeks. The primary outcome was smoking abstinence rates at week 12, defined as prolonged abstinence (no smoking from two weeks after the target quit date) and seven-day point-prevalence abstinence (no smoking past seven days). Outcomes were confirmed with an exhaled breath test for carbon monoxide.

Combination therapy was associated with significantly higher prolonged smoking abstinence rates at 12 (53 percent vs. 43.2 percent) and 26 weeks (36.6 percent vs. 27.6 percent) compared with varenicline alone. No significant differences were observed between the two groups at any time point for seven-day point-prevalence smoking abstinence. Anxiety was reported more commonly with combination therapy than with varenicline monotherapy (7.2 percent vs. 3.1 percent), as were depressive symptoms (3.6 percent vs. 0.8 percent).

Additional analyses revealed that the beneficial effects of combination therapy were stronger in heavier and more dependent smokers.

"For lighter smokers, using varenicline alone is just as effective as using both medications together," says Dr. Ebbert. "But, if you're a heavy smoker, you really should consider using combination therapy to increase your success of quitting."


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jon O. Ebbert, Dorothy K. Hatsukami, Ivana T. Croghan, Darrell R. Schroeder, Sharon S. Allen, J. Taylor Hays, Richard D. Hurt. Combination Varenicline and Bupropion SR for Tobacco-Dependence Treatment in Cigarette Smokers. JAMA, 2014; 311 (2): 155 DOI: 10.1001/jama.2013.283185

Cite This Page:

Mayo Clinic. "Combined therapy benefits cigarette smokers trying to quit compared to monotherapy." ScienceDaily. ScienceDaily, 7 January 2014. <www.sciencedaily.com/releases/2014/01/140107163735.htm>.
Mayo Clinic. (2014, January 7). Combined therapy benefits cigarette smokers trying to quit compared to monotherapy. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2014/01/140107163735.htm
Mayo Clinic. "Combined therapy benefits cigarette smokers trying to quit compared to monotherapy." ScienceDaily. www.sciencedaily.com/releases/2014/01/140107163735.htm (accessed August 30, 2014).

Share This




More Mind & Brain News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill 'trips' May Reduce Falls for Elderly

Treadmill 'trips' May Reduce Falls for Elderly

AP (Aug. 28, 2014) Scientists are tripping the elderly on purpose in a Chicago lab in an effort to better prevent seniors from falling and injuring themselves in real life. (Aug.28) Video provided by AP
Powered by NewsLook.com
Alice in Wonderland Syndrome

Alice in Wonderland Syndrome

Ivanhoe (Aug. 27, 2014) It’s an unusual condition with a colorful name. Kids with “Alice in Wonderland” syndrome see sudden distortions in objects they’re looking at or their own bodies appear to change size, a lot like the main character in the Lewis Carroll story. Video provided by Ivanhoe
Powered by NewsLook.com
Stopping Schizophrenia Before Birth

Stopping Schizophrenia Before Birth

Ivanhoe (Aug. 27, 2014) Scientists have long called choline a “brain booster” essential for human development. Not only does it aid in memory and learning, researchers now believe choline could help prevent mental illness. Video provided by Ivanhoe
Powered by NewsLook.com
Personalized Brain Vaccine for Glioblastoma

Personalized Brain Vaccine for Glioblastoma

Ivanhoe (Aug. 27, 2014) Glioblastoma is the most common and aggressive brain cancer in humans. Now a new treatment using the patient’s own tumor could help slow down its progression and help patients live longer. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins